Improvement in health status and quality of life in patients with osteoporosis treated with denosumab: results at a mean follow-up of six years
M. Mercurio, F. Familiari, R. de Filippis, C. Varano, F. Napoleone, O. Galasso, G. Gasparini Department of Orthopedic and Trauma Surgery, “Magna Graecia” University, “Mater Domini” University Hospital, Catanzaro, Italy. galasso@unicz.it
OBJECTIVE: The clinical efficacy and tolerability of denosumab in severe osteoporosis are well-known. However, the evaluation on general health and quality of life over time and compared to population norms is still lacking. We aimed at evaluating denosumab effectiveness in a real-world clinical sample with a 6-years average follow-up.
PATIENTS AND METHODS: In this retrospective-matched study with prospective data collection, a total of 101 patients affected by severe osteoporosis and treated with denosumab between 2014 and 2020 were evaluated. All patients completed the self-perceived quality of life (36-Item Short Form – SF-36) survey and visual analogue scale (VAS) before and after treatment.
RESULTS: Overall, 13 patients died of causes unrelated to the procedure, 12 stopped therapy with denosumab, and 30 did not participate in the follow-up; thus, 46 patients completed the study. There were 44 (95.7%) women and 93.4% of patients reported history of osteoporotic fractures. The mean follow-up was 59±17.8 months and the mean age at follow-up was 73.9±10.6 years. We found a significant improvement in bodily pain (baseline 53.8±33.4, follow-up 62.7±26.6; p=0.002) and in general health (baseline 35±25.4, follow-up 41.7±24.2; p=0.002) over time. The bodily pain score at follow-up was similar to the mean of the age-matched healthy population (62.7±26.6 vs. 67.6±26, p=0.374). The MCS-36 scores were higher than the normative values before treatment and at follow-up (51.6±9.8 vs. 45.8±9, p=0.004 and 50.6±11.7 vs. 45.8±9, p=0.030, respectively). The PCS-36 score at follow-up was comparable to the normative values (39.4±10.4 vs. 42.7±9, p=0.107).
CONCLUSIONS: Denosumab is effective to improve bone health and global mental and physical wellbeing, and quality of life over time.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
M. Mercurio, F. Familiari, R. de Filippis, C. Varano, F. Napoleone, O. Galasso, G. Gasparini
Improvement in health status and quality of life in patients with osteoporosis treated with denosumab: results at a mean follow-up of six years
Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 1 Suppl
Pages: 16-23
DOI: 10.26355/eurrev_202211_30278